Is Valeant Pharmaceuticals Intl Inc. Still a Good Buy?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been in the cross hairs of the media recently, and the stock has tanked considerably. Does this still make the company a good buy?

The Motley Fool

The incredible growth story of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has entered a cooling down phase—maybe.

Valeant has experienced almost unprecedented growth over the past few years—the stock has grown by 45% in the past year, and over the course of the past five years the stock is up by over 700%. The incredible thing about these figures is that they are actually down from what they were as recent as a few weeks ago.

Let’s take a look at why Valeant dropped and whether or not the company is still a good buy.

Valeant is a pharmaceutical company that is focuses on growth through acquisitions. The company has an extensive distribution network that is used for the myriad of companies that Valeant has acquired over the years.

The company has acquired seven companies just this year, and isn’t afraid to spend big on getting the company they are after. As recent as a few weeks ago, the company acquired the manufacturer of the drug Addyi, more commonly known as the female Viagra, for a reported $1 billion.

This model has worked well for Valeant, but recently the company has been subject of a sell-off, sparked by a single tweet from Democratic presidential candidate Hillary Clinton.

The tweet that caused a massive sell-off

Clinton tweeted of her intention to address what she claimed was price gouging: “Price gouging like this in the specialty drug market is outrageous. Tomorrow I’ll lay out a plan to take it on.”

 The focus of the tweet was a drug offered by another company, but that did not prevent Valeant from being drawn into the spotlight as well. Valeant’s heart drugs Nitropress and Isuprel increased in price by over 210% and 520% each the day that Valeant acquired the rights to sell them.

 The subsequent sell-off saw Valeant lose a significant portion of its value over the course of a few days—nearly 20%— and Democrats in the U.S. are asking to subpoena the company for documents relating to the price increases.

 Valeant CEO Mike Pearson addressed the pricing concerns in a letter to all employees: “Valeant is well positioned for strong organic growth, even assuming little to no price increases.”

The market seems to believe this as well, with the stock recouping a good portion of the losses from the sell-off in the days that followed. Currently, the stock is just over $238, but, incredibly, is still up over 28% year-to-date.

In my opinion, Valeant remains a great buy for investors seeking long-term growth. The fact that the stock can be purchased at a significant discount without any changes to the company’s growth prospects is an opportunity that investors should seize.

Fool contributor Demetris Afxentiou has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »